Cargando…

Antitumour activity of TH1579, a novel MTH1 inhibitor, against castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC) treatment still remains difficult. The aim of the present study was to determine the antitumour efficacy of the MutT homolog 1 (MTH1) inhibitor, TH1579, against castration-resistant prostate cancer. PC-3 and DU-145 prostate cancer cells were treated with d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Mingqiu, Ning, Jing, Mao, Likai, Yu, Yuanyuan, Wu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709546/ https://www.ncbi.nlm.nih.gov/pubmed/33281973 http://dx.doi.org/10.3892/ol.2020.12324

Ejemplares similares

TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model
por: Moukengue, Brice, et al.
Publicado: (2020)

MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia
por: Sanjiv, Kumar, et al.
Publicado: (2021)

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
por: Omlin, A, et al.
Publicado: (2013)

Relación de Misantla: 1579
por: Pérez de Arteaga, Diego
Publicado: (2018)

Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer
por: Mao, Yifeng, et al.
Publicado: (2022)

Effect of Microstructure on the Corrosion Resistance of TIG Welded 1579 Alloy
por: Gnedenkov, Andrey S., et al.
Publicado: (2019)

Potent and specific MTH1 inhibitors targeting gastric cancer
por: Zhou, Wenjuan, et al.
Publicado: (2019)

The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia
por: Pompsch, Mosche, et al.
Publicado: (2018)

Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancer
por: Wang, Fangming, et al.
Publicado: (2022)

1579. Burkholderia Returns: Are Two Drugs Better or Back to Bactrim?
por: Hedvat, Jason, et al.
Publicado: (2020)

Correction: Potent and specific MTH1 inhibitors targeting gastric cancer
por: Zhou, Wenjuan, et al.
Publicado: (2020)

Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2
por: Carter, Megan, et al.
Publicado: (2015)

Farnesyl phenolic enantiomers as natural MTH1 inhibitors from Ganoderma sinense
por: Gao, Ya, et al.
Publicado: (2017)

Overexpressed c-Myc Sensitizes Cells to TH1579, a Mitotic Arrest and Oxidative DNA Damage Inducer
por: Henriksson, Sofia, et al.
Publicado: (2022)

PReS13-SPK-1579: Biologic agents for the treatment of rheumatic diseases
por: Emery, P
Publicado: (2013)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Relaciones y memorias de la provincia de Michoacán, 1579-1581
Publicado: (1985)

The MTH1 inhibitor TH588 is a microtubule-modulating agent that eliminates cancer cells by activating the mitotic surveillance pathway
por: Gul, Nadia, et al.
Publicado: (2019)

A catalase inhibitor: Targeting the NADPH-binding site for castration-resistant prostate cancer therapy
por: Cao, Ya Ya, et al.
Publicado: (2023)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023)

Understanding the molecular mechanism for the differential inhibitory activities of compounds against MTH1
por: Wang, Mian, et al.
Publicado: (2017)

MTH1 counteracts oncogenic oxidative stress
por: Burton, Dominick G.A., et al.
Publicado: (2015)

Polyamine block of MthK potassium channels
por: Nimigean, Crina M.
Publicado: (2020)

The allosteric gating mechanism of the MthK channel
por: Guan, Fenghui, et al.
Publicado: (2022)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

MTH1 inhibitor amplifies the lethality of reactive oxygen species to tumor in photodynamic therapy
por: Zhao, Lingzhi, et al.
Publicado: (2020)

Targeting the MLL complex in castration resistant prostate cancer
por: Malik, Rohit, et al.
Publicado: (2015)

Phase separation of Arabidopsis EMB1579 controls transcription, mRNA splicing, and development
por: Zhang, Yiling, et al.
Publicado: (2020)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Expansion of mouse castration-resistant intermediate prostate stem cells in vitro
por: Xu, Yalan, et al.
Publicado: (2022)

1579. Multidrug-Resistant Candida auris Isolates From New York Hospitals and Healthcare Facilities Are Susceptible to Antifungal Combinations
por: O’Brien, Brittany, et al.
Publicado: (2019)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
por: Sonnenburg, Daniel, et al.
Publicado: (2018)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
por: Coulter, Jonathan B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ga2v8bs45uo25il7p016rfe07